The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells.
Several studies have stressed the importance of the microbiota in the maintenance of the gastrointestinal epithelium. Administration of probiotic bacteria, supplements composed of microbiota constituents, was previously shown to diminish symptoms in patients suffering from inflammatory bowel diseases. This raises the possibility that probiotics may play an active role in enhancing the intestinal barrier at the mucosal surface. In this study, we investigated whether the clinically tested VSL#3 probiotic formula and/or its secreted components can augment the protective mucus layer in vivo and in vitro. For in vivo studies, Wistar rats were orally administered the probiotic mixture VSL#3 on a daily basis for seven days. After treatment, basal luminal mucin content increased by 60%. In addition, we exposed isolated rat colonic loops to the VSL#3 probiotic formula, which significantly stimulated colonic mucin (MUC) secretion and MUC2 gene expression; however, MUC1 and MUC3 gene expression were only slightly elevated. The effect of the VSL#3 mucin secretagogue was also tested in vitro by use of LS 174T colonic epithelial cells. In contrast to the animal studies, cultured cells incubated with VSL#3 bacteria did not exhibit increased mucin secretion. However, the bacterial secreted products contained in the conditioned media stimulated a remarkable mucin secretion effect. Among the three bacterial groups (Lactobacilli, Bifidobacteria, and Streptococci) contained in VSL#3, the Lactobacillus species were the strongest potentiator of mucin secretion in vitro. A preliminary characterization of the putative mucin secretagogue suggested that it was a heat-resistant soluble compound, which is not sensitive to protease and DNase treatment. These findings contribute to a better understanding of the complex and beneficial interaction between colonic epithelial cells and intestinal bacteria.
Caballero-Franco
C
C
Institute of Parasitology, McGill University, Saint Anne de Bellevue, Quebec, Canada.
Keller
K
K
De Simone
C
C
Chadee
K
K
D000818:Animals; D001644:Bifidobacterium; D002460:Cell Line; D003106:Colon / Q000502:physiology*; D017931:DNA Primers; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000502:physiology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D005944:Glucosamine / Q000378:metabolism; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000502:physiology*; D007778:Lactobacillus; D008297:Male; D018396:Mucin-1 / Q000235:genetics; D055262:Mucin-2; D009077:Mucins / Q000235:genetics*; D016133:Polymerase Chain Reaction; D019936:Probiotics / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013291:Streptococcus
D017931:DNA Primers; C524625:MUC2 protein, human; C524628:Muc2 protein, rat; D018396:Mucin-1; D055262:Mucin-2; D009077:Mucins; D005944:Glucosamine